Soft Tissue Sarcoma

P2, N=27, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial primary completion date: Apr 2026 --> Dec 2026

P2, N=15, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting | Trial completion date: Sep 2027 --> Jun 2027 | Initiation date: Dec 2025 --> Sep 2025

The algorithm also performed robustly in the TCGA-SARC data, although with a slightly different optimal cutoff, likely due to differences in gene panels, depth of sequencing, gene coverage, and bioinformatics pipelines. This study presents an effective strategy for screening DDLPS and potentially other MDM2-amplified sarcomas.

Our results also demonstrate that inducible knockdown of TAK1 in human RMS xenografts retards tumor growth and enhances myogenic differentiation in vivo. Collectively, these findings uncover a previously unrecognized role for TAK1 in RMS growth and differentiation, and suggest that TAK1 can be a potential therapeutic target for the treatment of RMS.

This is the first reported case of sclerosing epithelioid dermatofibroma exhibiting diffuse cytokeratin and p40/p63 expression. Recognizing this atypical immunophenotype is crucial to avoid diagnostic pitfalls, as it may mimic malignant epithelial or mesenchymal neoplasms such as sarcomatoid squamous cell carcinoma or epithelioid sarcoma. The expression likely reflects phenotypic plasticity rather than true epithelial malignancy.

P=N/A, N=100, Not yet recruiting, St. Jude Children's Research Hospital

P1, N=40, Active, not recruiting, Iovance Biotherapeutics, Inc. | Recruiting --> Active, not recruiting

P2, N=20, Suspended, M.D. Anderson Cancer Center | Not yet recruiting --> Suspended

P=N/A, N=42, Recruiting, University Hospital Heidelberg | Trial completion date: Jul 2026 --> Jul 2029 | Trial primary completion date: Jul 2026 --> Jul 2028

Surgical margins were negative, and one-year follow-up showed that the patient remained disease-free. This case highlights the importance of immunohistochemistry and molecular testing for accurate diagnosis and appropriate management.

Conclusions Due to their rarity, these tumors may be overlooked in clinical practice. The low availability of diagnostic tests in many centers may contribute to the underestimation of the incidence of SFTs.

Immunohistochemistry plays a crucial role in interpreting a specific diagnosis or narrowing the differential diagnosis of SRCTs. Molecular genetic investigations are essential, particularly in cases exhibiting atypical or overlapping histologic and immunohistological features.